Effective November 27, 2021 all students participating in resident training at the National Emergency Training Center (NETC) for the National Fire Academy (NFA) or Emergency Management Institute (EMI) must be fully vaccinated*. This additional mitigation measure is to provide a safe learning and working environment for all students, instructors, and staff on the NETC campus.
Upon arrival on the NETC campus, students must provide visual proof of their vaccination status to authorized NETC personnel (NETC Housing Desk, Building C-West).
Acceptable documentation includes a physical or electronic copy of:
- The record of immunization from a health care provider or pharmacy.
- A COVID-19 Vaccination Record Card (CDC Form MLS-319813_r, published on 9/3/2020).
- Medical records documenting the vaccination.
- Immunization records from a public health of state immunization system.
- Any other official documentation containing:
- Type of vaccine administered
- Numbers of doses received
- Date(s) of administration, and
- Name of the health care professional(s) or clinic site(s) administering the vaccine(s)
The NETC campus will no longer accept a negative COVID-19 test, or other accommodations, to attend in-person training. On-campus testing will not be available. In addition, please refrain from traveling to NETC if you are “ill” in any fashion.
If you are unable to meet this requirement, please contact the NETC Admissions Office at email@example.com or at 301-447-1035 to withdraw from your course(s). NETC Admissions personnel can reschedule you for a future class when you are able to meet the campus vaccination requirements.
*Definition of Fully Vaccinated:
A person is considered fully vaccinated two weeks after they receive the requisite number of doses of an approved COVID-19 vaccine including those authorized for emergency use by the U.S. Food and Drug Administration or that has been listed for emergency use by the World Health Organization.
- Pfizer-BioNTech, Moderna or AstraZeneca/Oxford: require a two-dose series.
- Johnson and Johnson (J&J)/Janssen: requires a single dose.
- Clinical trial participants from a U.S. site who are documented to have received the full series of an “active” (not placebo) COVID-19 vaccine candidate, for which vaccine efficacy has been independently confirmed, are considered fully vaccinated two weeks after they complete the vaccine series. Currently the Novavax COVID-19 vaccine meets these criteria.